New stock news | Zhejiang Jing pharmaceutical (688266.SH) submits listing application to Hong Kong Stock Exchange.

According to the disclosure on December 19 by the Hong Kong Stock Exchange, Suzhou Zejing Biopharmaceutical Co., Ltd. (referred to as Zejing Pharmaceuticals) (688266.SH) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC as its sole sponsor. The prospectus shows that Zejing Biopharmaceutical is a comprehensive biopharmaceutical company, focusing on the discovery, research and commercialization of innovative small molecule and biological therapy, strategically focusing on the three major treatment areas of oncology, autoimmune diseases, and hemostasis/blood diseases. Zejing Pharmaceuticals' product portfolio and pipeline cover marketed drugs, late-stage clinical candidate drugs, and early-stage discovery projects at the forefront of innovation. Currently, Zejing Pharmaceuticals has three marketed drugs: ZepuSheng, China's first domestically developed small molecule multi-targeted drug for first-line treatment of advanced liver cancer; ZepuPing, China's first domestically developed innovative JAK inhibitor for the treatment of myelofibrosis; ZepuNing, China's only recombinant human thrombin developed and successfully commercialized using recombinant DNA technology.